An overview of unlocking the power of non-coding RNAs in revolutionizing cancer therapy

Abstract

Non-coding RNA (ncRNA) has been recognized to be an essential regulator of cellular processes and gene expression in cancer. The present study covers the various roles of ncRNAs, including circular RNAs (circRNAs), long non-coding RNAs (lncRNAs), and microRNAs (miRNAs), that affect cancer properties. Oncogenesis, metastasis, and treatment resistance are all processes involving ncRNAs, which have tremendous potential as new therapeutic agents and targets. The review covers the broad spectrum of ncRNAs in cancer biology, including their types and activities, epigenetic control, function in metastasis and angiogenesis, detection and profiling approaches, potential as biomarkers, and therapeutic possibilities. Recent advancements in next-generation sequencing and other molecular methods have helped us better understand how ncRNAs work and their potential therapeutic uses. However, there are still challenges to standardizing detection technologies and producing effective RNA-based therapeutics. Therefore, further studies are needed to solve important issues in this sector. Standardization efforts are also essential to developing identical methods for ncRNA collection, quantification, and analysis throughout multiple laboratories and ensuring the findings are reliable and comparable. Large-scale, multi-recentre studies are required to verify the diagnostic usefulness of ncRNA biomarkers across a wide range of patient groups. Also, more detailed mechanistic knowledge is necessary for understanding the particular molecular mechanisms by which ncRNAs affect cancer growth, metastasis, and treatment response. This review highlights the complex relationships between ncRNAs and cancer biology and also focuses on their potential effect on cancer diagnosis and treatment. It also highlights the necessity for more studies to fully understand the therapeutic potential of ncRNAs in cancer. As studies advance, using ncRNA results in clinical practice might change cancer treatment by novel opportunities for specific therapy and personalized medicine.